CereVu Medical

What CereVu Medical does

CereVu Medical is a San Francisco-based private medical technology company founded in 2018 that develops an AI-driven wearable sensor for the objective measurement of pain and dyspnea. The device combines a near-infrared spectroscopy (NIRS) sensor array with continuous vital signs monitoring (heart rate, SpO2, respiratory rate, body activity, and coughing dynamics) and applies proprietary AI algorithms to translate cerebral hemodynamic signals into personalized pain and dyspnea indices. The technology is investigational and has not been cleared or approved by the U.S. Food and Drug Administration, and the company explicitly states it is intended for research and evaluation purposes only, not for clinical diagnosis, treatment, or medical decision-making.

The company's core evidence base consists of five clinical studies covering more than 400 patients across acute pain (Stanford University, 109 subjects, 0.95 AUC), chronic pain with epidural steroid injection (50 subjects), and labor & delivery (Stanford L&D Department, 130 subjects), with reported accuracy above 90%. Research has been published in peer-reviewed venues including the Journal of Pain Research (2018) and MDPI IJERPH (2022), and the company was featured in Nature Magazine in September 2024.

Commercially, CereVu has no disclosed customers, pricing, or revenue. The company has raised over $2M in non-dilutive grant funding from the National Science Foundation and the U.S. Food and Drug Administration, with prior NSF grants of $256K (2020) and $1M (2021). Its primary external relationship is a research partnership with Stanford University, and its go-to-market is currently restricted to clinical research collaborations rather than commercial product distribution. The headcount is reported at 1-10 employees, consistent with a pre-commercial R&D-stage medical device company.

Name

CereVu Medical

Legal name

CereVu Medical

Website

https://cerevu.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

CereVu Medical is a San Francisco-based private company developing an AI-driven, investigational wearable sensor that uses near-infrared spectroscopy and proprietary algorithms to provide objective, continuous measurement of pain and dyspnea, validated across 400+ patients in clinical studies with Stanford University.

Ownership category

akta.pro rank

Product category

Medical Wearable Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)

Keywords

• Wearable pain monitoring
• Near-infrared spectroscopy
• Objective pain measurement
• Cerebral hemodynamic assessment
• Clinical vital signs monitoring

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

CereVu Medical develops an investigational AI-driven wearable sensor array that provides objective, continuous measurement of pain and dyspnea. The device uses near-infrared spectroscopy to capture cerebral oxygenation changes and proprietary AI algorithms to translate those changes into personalized pain indices, while simultaneously capturing routine vital signs (heart rate, SpO2, respiratory rate), body activity, and coughing dynamics. The technology is currently investigational and intended for research and evaluation purposes only, not for clinical diagnosis, treatment, or medical decision-making.

Product overview

CereVu Medical offers a single unified product—a wearable sensor system for objective pain and dyspnea measurement. The device uses near-infrared spectroscopy to capture cerebral hemodynamic responses, which proprietary AI algorithms process to generate personalized pain indices. The system also continuously monitors routine vital signs (heart rate, SpO2, respiratory rate), body activity, and coughing dynamics. All monitoring and biomarker assessment capabilities are integrated into one investigational wearable device that has not yet received FDA clearance or approval.

Differentiator

Problem solved

Functional benefit

Products and services

• CereVu Wearable Pain Assessment Sensor

Quantifiable outcome

• >90% accuracy in pain assessment across clinical studies
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

One partnership is on record.

• Stanford UniversitycoreStrategic or Co-development PartnerAcademic research partnership with Stanford University's Labor & Delivery Department and broader medical research divisions. Conducted multiple clinical validation studies including acute pain study (109 subjects) and labor & delivery monitoring (130 subjects).

Scale indicators8 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• GE HealthCare: GE HealthCare's patient monitoring solutions (including wearable vital-sign monitors through its Vital Signs portfolio) compete in the same hospital physiology-monitoring category. Their installed hospital base makes them a benchmark for enterprise distribution CereVu would need to match or partner with.
• Edwards Lifesciences: Edwards provides advanced hemodynamic and patient monitoring (FloTrac, ClearSight, HemoSphere) used in perioperative and ICU settings where CereVu's cerebral hemodynamic and pain biomarkers would also be deployed. Comparable in generating AI-derived, continuous clinical decision-support metrics from physiological waveforms.
• Masimo: Masimo is a leading global patient monitoring company whose SET pulse oximetry and rainbow sensors monitor SpO2 and other parameters that CereVu also captures. They are a broader incumbent that has begun expanding into objective assessment, making it a natural competitor and potential strategic acquirer for CereVu's pain-specific biomarker.
• Medtronic: Medtronic is a broad medtech incumbent with neuromonitoring (BrainSense, NIM), patient monitoring, and pain-related device franchises. Most relevant as a large incumbent CereVu would either compete with at the edge or partner/acquire with for distribution and FDA infrastructure.
• Philips Patient Monitoring: Philips provides continuous patient monitoring systems (IntelliVue, wearable biosensors) that capture many of the same vital signs as CereVu's device. Comparable in targeting hospital/ED workflows with continuous physiology data, but operates at vastly broader scale across the full monitoring stack.

Direct peers

• Empatica: Empatica makes FDA-cleared wearable sensors (EpiMonitor for epilepsy, Embrace for autism) that use proprietary biosignal algorithms to derive clinical endpoints from continuous physiology. Directly comparable as a small, AI-first wearable medical-device company pursuing novel biomarker applications.
• VitalConnect: VitalConnect produces the VitalPatch wearable biosensor for continuous patient monitoring of cardiac, respiratory, and SpO2 metrics in hospital and remote settings. Shares the same wearable-sensor + AI-data-stream model and target buyers (enterprise hospital and RPM programs) as CereVu.
• Medasense Biometrics: Medasense develops the PMD200 with the NOL (Nociception Level) index, a similar AI-driven, objective pain-monitoring technology used in surgical and critical-care settings. Directly comparable to CereVu in solving subjective pain assessment with a sensor + proprietary algorithm approach.

Emerging players

• iRhythm Technologies: iRhythm commercializes the Zio wearable cardiac monitor with AI-based arrhythmia detection, validating a business model of wearable sensor + proprietary AI biomarker + enterprise reimbursement. A relevant comparator for CereVu's regulatory and commercial pathway for novel biomarker diagnostics.

Regional players

• Compumedics: Compumedics is a neurological diagnostics company (EEG, sleep, brain monitoring) with a comparable wearable/sensor-based neurological monitoring portfolio. Strong adjacency to CereVu's NIRS-based cerebral monitoring paradigm, though primarily active in sleep and laboratory diagnostics outside the U.S. acute-care market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cerevu-medical

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CereVu Medical